Recent 59 Minute Interview With Fabian Baker - Worth Watching, page-27

First 27 Last

Share
Profile

Follow
Pharrell13

1,776 Posts.

677

01/06/24

00:10

Post #: 74113774
Share

Originally posted by Swakopmunder: ↑

TBH like 99% of global Ni projects, Rana has been looked at and picked over many times in the last many decades. What the world needs is a new Ni story (and a price rally). Rana is not it. Too difficult on many levels.

And costly, last 5B shows a AUD$4MM burn...

Good deal with BHP but that ground looked over a few times before as well. Will take a long time to crystalise any value at all in that lot, won't it? Holding costs won't be small either, like Rana etc.

As for Penikat, it is certainly intruiging, but OK were a good outfit, it's v. well known, and its been ages on the back-burner, it's gone through multiple PGM cycles with no progress. So again, you need to ask why that is? Will it ever get off the ground?

Management seem not to think so either? - even looking at opportunities in the Katangan or in the Balkans appears a bit irrelevant really, There's history in Balkans as there was in Armenia - all these things were well known to the Sovs and underdrilled before mining began, so great opportunities for western companies to go in do a bit of modern work and away to the races, claiming excellence.

More difficult nowadays. Sure they have an excellent treasury and great support.

Still undecided personally. Open to logic though.

IMHO and DYOR, but regardless GLTAH

Expand

I’m happy to back KRM management & BHPs metrics with the current portfolio of projects… Having spent 20
years in the BHP system I am acutely aware of the scrutiny they place on exploration, & alliances.

Last edited by Pharrell13: 01/06/24

KRM Price at posting: 5.2¢ Sentiment: Buy Disclosure: Held
18 Upvote

4 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 5 more messages in this thread...

First 27 Last

Add KRM (ASX) to my watchlist

(20min delay)
Last 3.8¢		Change -0.001(2.56%)		Mkt cap ! $28.63M

Open	High	Low	Value	Volume
3.8¢	3.8¢	3.8¢	$800	21.05K

Buyers (Bids)

No.	Vol.	Price($)
1	79999	3.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	126655	2

View Market Depth

No.	Vol.	Price($)
1	79999	0.038
1	200000	0.036
3	424546	0.035
2	289685	0.033
2	343333	0.032

Price($)	Vol.	No.
0.040	126655	2
0.041	12195	1
0.042	300000	1
0.043	59999	1
0.044	15460	1

Last trade - 10.04am 07/10/2024 (20 minute delay)

KRM (ASX) Chart

Recent 59 Minute Interview With Fabian Baker - Worth Watching, page-27

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Recent 59 Minute Interview With Fabian Baker - Worth Watching, page-27

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News